BIOGEN INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
BIOGEN INC. (BIIB) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $41.80 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-04-29
- BIOGEN INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was $41.80M.
- BIOGEN INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was -$45.80M, a 582.11% decline year-over-year.
- BIOGEN INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $23.30M, a 7666.67% increase year-over-year.
- BIOGEN INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was -$63.60M, a 538.62% decline year-over-year.
- BIOGEN INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$45.80M, a 361.71% decline from fiscal 2024.
- BIOGEN INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $17.50M, a 56.25% increase from fiscal 2023.
- BIOGEN INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $11.20M.
- BIOGEN INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$58.20M, a 130.27% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $41.80M 10-Q · filed 2026-04-29 | -$4.00M derived: sum of 2 quarters · filed 2026-04-29 | $19.30M derived: sum of 3 quarters · filed 2026-04-29 | -$44.30M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2025-12-31 | -$45.80M 10-K · filed 2026-02-06 | -$22.50M derived: sum of 2 quarters · filed 2026-02-06 | -$86.10M derived: sum of 3 quarters · filed 2026-02-06 | -$45.80M 10-K · filed 2026-02-06 | |
| 2025-09-30 | $23.30M 10-Q · filed 2025-10-30 | -$40.30M derived: sum of 2 quarters · filed 2025-10-30 | -$78.60M 10-Q · filed 2025-10-30 | -$69.10M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2025-06-30 | -$63.60M 10-Q · filed 2025-07-31 | -$101.90M 10-Q · filed 2025-07-31 | -$92.40M derived: sum of 3 quarters · filed 2026-04-29 | -$92.10M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2025-03-31 | -$38.30M 10-Q · filed 2026-04-29 | -$28.80M derived: sum of 2 quarters · filed 2026-04-29 | -$28.50M derived: sum of 3 quarters · filed 2026-04-29 | -$14.00M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2024-12-31 | $9.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $9.80M derived: sum of 2 quarters · filed 2026-02-06 | $24.30M derived: sum of 3 quarters · filed 2026-02-06 | $17.50M 10-K · filed 2026-02-06 | |
| 2024-09-30 | $300.00K 10-Q · filed 2025-10-30 | $14.80M derived: sum of 2 quarters · filed 2025-10-30 | $8.00M 10-Q · filed 2025-10-30 | $13.60M derived: sum of 4 quarters · filed 2026-02-06 | |
| 2024-06-30 | $14.50M 10-Q · filed 2025-07-31 | $7.70M 10-Q · filed 2025-07-31 | $13.30M derived: sum of 3 quarters · filed 2026-02-06 | $26.80M derived: sum of 4 quarters · filed 2026-02-06 | |
| 2024-03-31 | -$6.80M 10-Q · filed 2025-05-01 | -$1.20M derived: sum of 2 quarters · filed 2026-02-06 | $12.30M derived: sum of 3 quarters · filed 2026-02-06 | $11.50M derived: sum of 4 quarters · filed 2026-02-06 | |
| 2023-12-31 | $5.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $19.10M derived: sum of 2 quarters · filed 2026-02-06 | $18.30M derived: sum of 3 quarters · filed 2026-02-06 | $11.20M 10-K · filed 2026-02-06 | |
| 2023-09-30 | $13.50M 10-Q · filed 2024-10-30 | $12.70M derived: sum of 2 quarters · filed 2024-10-30 | $5.60M 10-Q · filed 2024-10-30 | $4.30M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-06-30 | -$800.00K 10-Q · filed 2024-08-01 | -$7.90M 10-Q · filed 2024-08-01 | -$9.20M derived: sum of 3 quarters · filed 2025-02-12 | -$62.40M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-03-31 | -$7.10M 10-Q · filed 2024-04-24 | -$8.40M derived: sum of 2 quarters · filed 2025-02-12 | -$61.60M derived: sum of 3 quarters · filed 2025-02-12 | -$56.80M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2022-12-31 | -$1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$54.50M derived: sum of 2 quarters · filed 2025-02-12 | -$49.70M derived: sum of 3 quarters · filed 2025-02-12 | -$58.20M 10-K · filed 2025-02-12 | |
| 2022-09-30 | -$53.20M 10-Q · filed 2023-11-08 | -$48.40M derived: sum of 2 quarters · filed 2023-11-08 | -$56.90M 10-Q · filed 2023-11-08 | -$27.00M derived: sum of 4 quarters · filed 2024-02-14 | |
| 2022-06-30 | $4.80M 10-Q · filed 2023-07-25 | -$3.70M 10-Q · filed 2023-07-25 | $26.20M derived: sum of 3 quarters · filed 2024-02-14 | $61.40M derived: sum of 4 quarters · filed 2024-02-14 | |
| 2022-03-31 | -$8.50M 10-Q · filed 2023-04-25 | $21.40M derived: sum of 2 quarters · filed 2024-02-14 | $56.60M derived: sum of 3 quarters · filed 2024-02-14 | $59.10M derived: sum of 4 quarters · filed 2024-02-14 | |
| 2021-12-31 | $29.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $65.10M derived: sum of 2 quarters · filed 2024-02-14 | $67.60M derived: sum of 3 quarters · filed 2024-02-14 | $192.30M 10-K · filed 2024-02-14 | |
| 2021-09-30 | $35.20M 10-Q · filed 2022-10-25 | $37.70M derived: sum of 2 quarters · filed 2022-10-25 | $162.40M 10-Q · filed 2022-10-25 | $88.90M derived: sum of 4 quarters · filed 2023-02-15 | |
| 2021-06-30 | $2.50M 10-Q · filed 2022-07-20 | $127.20M 10-Q · filed 2022-07-20 | $53.70M derived: sum of 3 quarters · filed 2023-02-15 | $9.20M derived: sum of 4 quarters · filed 2023-02-15 | |
| 2021-03-31 | $124.70M 10-Q · filed 2022-05-03 | $51.20M derived: sum of 2 quarters · filed 2023-02-15 | $6.70M derived: sum of 3 quarters · filed 2023-02-15 | -$25.00M derived: sum of 4 quarters · filed 2023-02-15 | |
| 2020-12-31 | -$73.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$118.00M derived: sum of 2 quarters · filed 2023-02-15 | -$149.70M derived: sum of 3 quarters · filed 2023-02-15 | -$163.80M 10-K · filed 2023-02-15 | |
| 2020-09-30 | -$44.50M 10-Q · filed 2021-10-20 | -$76.20M derived: sum of 2 quarters · filed 2021-10-20 | -$90.30M 10-Q · filed 2021-10-20 | -$133.20M derived: sum of 4 quarters · filed 2022-02-03 | |
| 2020-06-30 | -$31.70M 10-Q · filed 2021-07-22 | -$45.80M 10-Q · filed 2021-07-22 | -$88.70M derived: sum of 3 quarters · filed 2022-02-03 | $71.90M derived: sum of 4 quarters · filed 2022-02-03 | |
| 2020-03-31 | -$14.10M 10-Q · filed 2021-04-22 | -$57.00M derived: sum of 2 quarters · filed 2022-02-03 | $103.60M derived: sum of 3 quarters · filed 2022-02-03 | $70.50M derived: sum of 4 quarters · filed 2022-02-03 | |
| 2019-12-31 | -$42.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | $117.70M derived: sum of 2 quarters · filed 2022-02-03 | $84.60M derived: sum of 3 quarters · filed 2022-02-03 | $105.20M 10-K · filed 2022-02-03 | |
| 2019-09-30 | $160.60M 10-Q · filed 2020-10-21 | $127.50M derived: sum of 2 quarters · filed 2020-10-21 | $148.10M 10-Q · filed 2020-10-21 | $156.00M derived: sum of 4 quarters · filed 2021-02-03 | |
| 2019-06-30 | -$33.10M 10-Q · filed 2020-07-22 | -$12.50M 10-Q · filed 2020-07-22 | -$4.60M derived: sum of 3 quarters · filed 2021-02-03 | $8.70M derived: sum of 4 quarters · filed 2021-02-03 | |
| 2019-03-31 | $20.60M 10-Q · filed 2020-04-23 | $28.50M derived: sum of 2 quarters · filed 2021-02-03 | $41.80M derived: sum of 3 quarters · filed 2021-02-03 | $84.10M derived: sum of 4 quarters · filed 2021-02-03 | |
| 2018-12-31 | $7.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $21.20M derived: sum of 2 quarters · filed 2021-02-03 | $63.50M derived: sum of 3 quarters · filed 2021-02-03 | $76.50M 10-K · filed 2021-02-03 | |
| 2018-09-30 | $13.30M 10-Q · filed 2019-10-22 | $55.60M derived: sum of 2 quarters · filed 2019-10-22 | $68.60M 10-Q · filed 2019-10-22 | ||
| 2018-06-30 | $42.30M 10-Q · filed 2019-07-24 | $55.30M 10-Q · filed 2019-07-24 | |||
| 2018-03-31 | $13.00M 10-Q · filed 2019-04-24 | ||||
| 2017-12-31 | $1.50M 10-K · filed 2020-02-06 | ||||
| 2016-12-31 | -$95.90M 10-K · filed 2019-02-06 | ||||
| 2015-12-31 | -$164.50M 10-K · filed 2018-02-01 | ||||
| 2014-12-31 | -$31.80M 10-K · filed 2017-02-02 | -$31.74M 10-K · filed 2015-02-04 | |||
| 2013-12-31 | $27.60M 10-K · filed 2016-02-03 | $27.56M 10-K · filed 2014-02-06 | |||
| 2013-03-31 | -$12.70M 10-Q · filed 2013-04-25 | ||||
| 2012-12-31 | -$28.77M 10-K · filed 2015-02-04 | ||||
| 2011-12-31 | -$4.92M 10-K · filed 2014-02-06 | ||||
| 2010-12-31 | -$72.11M 10-K · filed 2013-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |